AKAN saw its Momentum Indicator move below the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 78 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKAN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for AKAN just turned positive on October 21, 2026. Looking at past instances where AKAN's MACD turned positive, the stock continued to rise in 28 of 38 cases over the following month. The odds of a continued upward trend are 74%.
Following a +6.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKAN advanced for three days, in 140 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
AKAN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.188) is normal, around the industry mean (10.407). P/E Ratio (0.001) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.032) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. AKAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
On October 19, 2026, the Stochastic Oscillator for OGI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 74 instances where the indicator left the oversold zone. In 61 of the 74 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OGI's RSI Oscillator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for OGI just turned positive on October 20, 2026. Looking at past instances where OGI's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
OGI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OGI as a result. In 77 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
OGI moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OGI crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OGI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.278) is normal, around the industry mean (10.407). P/E Ratio (1.533) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.650) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. OGI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
OGI | ||
|---|---|---|
OUTLOOK RATING 1..100 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 46 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AKAN | OGI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 76% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 82% | N/A |
| Declines ODDS (%) | 3 days ago 90% | 9 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKAN’s FA Score shows that 1 FA rating(s) are green while OGI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKAN’s TA Score shows that 4 TA indicator(s) are bullish while OGI’s TA Score has 4 bullish TA indicator(s).
AKAN (@Pharmaceuticals: Generic) experienced а -15.79% price change this week, while OGI (@Pharmaceuticals: Generic) price change was +4.06% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
OGI is expected to report earnings on Dec 15, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that AKAN and CGC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and CGC's prices will move in lockstep.
| Ticker / NAME | Correlation To AKAN | 1D Price Change % | ||
|---|---|---|---|---|
| AKAN | 100% | +2.68% | ||
| CGC - AKAN | 30% Poorly correlated | -1.00% | ||
| OGI - AKAN | 26% Poorly correlated | -0.43% | ||
| SNOA - AKAN | 25% Poorly correlated | N/A | ||
| SNDL - AKAN | 24% Poorly correlated | +0.78% | ||
| ACB - AKAN | 23% Poorly correlated | +0.25% | ||
More | ||||
A.I.dvisor indicates that over the last year, OGI has been closely correlated with SNDL. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if OGI jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To OGI | 1D Price Change % | ||
|---|---|---|---|---|
| OGI | 100% | -0.43% | ||
| SNDL - OGI | 67% Closely correlated | +0.78% | ||
| ACB - OGI | 64% Loosely correlated | +0.25% | ||
| CGC - OGI | 58% Loosely correlated | -1.00% | ||
| TLRY - OGI | 51% Loosely correlated | +0.34% | ||
| TRLV - OGI | 49% Loosely correlated | -0.73% | ||
More | ||||